Get a free sample of Infectious Enteritis Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Infectious Enteritis Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Infectious Enteritis Treatment Market Size
Infectious Enteritis Treatment Market size was valued at USD 434.8 million in 2023 and is estimated to grow at 6.3% CAGR from 2024 to 2032. The market has seen notable expansion, largely propelled by the rising incidence of infectious diseases globally. Factors such as contaminated food and water sources, as well as insufficient sanitation, play a role in the transmission of enteric pathogens.
For instance, World Health Organization (WHO) reported that each year unsafe food causes 600 million cases of foodborne diseases and 420,000 deaths globally. Therefore, the increasing prevalence of foodborne illnesses leading to gastrointestinal disorders, including enteritis, contributes to an increasing demand for treatment, thereby driving market growth.
Infectious enteritis treatment refers to the medical interventions aimed at managing and alleviating symptoms associated with enteritis, an inflammation of the small intestine typically caused by infectious agents such as bacteria, viruses, or parasites. Treatment strategies may include antibiotics, antiviral drugs, fluid and electrolyte replacement therapy, dietary modifications, and supportive care to relieve symptoms and promote recovery from the infection.
Who are the major infectious enteritis treatment industry players?
Abbott Laboratories, Almirall SA, AstraZeneca PLC, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, GSK plc, Medimetriks Pharmaceuticals Inc., Merck KGaA, and Pfizer Inc. among others.
Why is infectious enteritis treatment preferred in the U.S.?
U.S. infectious enteritis treatment market size was 167.9 million in 2023 and will show significant growth over the analysis period, driven by favorable regulatory frameworks, coupled with the introduction of advanced products.
Why is the demand for antibiotics rising in the infectious enteritis treatment industry?
Infectious enteritis treatment industry from the antibiotics drug type segment will reach USD 388.5 million by end of 2032, owing to its ability to effectively target various enteric infections in adults.
How much is the infectious enteritis treatment industry worth?
The infectious enteritis treatment market size was valued at USD 434.8 million in 2023 and will grow at 6.3% CAGR from 2024 to 2032, propelled by the rising incidence of infectious diseases globally.